{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:47:21Z","timestamp":1787316441626,"version":"build-2736575974"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T00:00:00Z","timestamp":1644624000000},"content-version":"vor","delay-in-days":376,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004361","name":"Krebsliga Schweiz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004361","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011912","name":"Washington University School of Medicine in St. Louis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001388","name":"Wenner-Gren Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001388","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007338","name":"Foundation for Barnes-Jewish Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007338","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.medj.2020.10.006","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T11:39:10Z","timestamp":1606995550000},"page":"180-195.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Systemic Protein Deviation Score Linked to PD-1+ CD8+ T Cell Expansion That Predicts Overall Survival in Diffuse Large B Cell Lymphoma"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8655-1433","authenticated-orcid":false,"given":"Eivind Heggernes","family":"Ask","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Tschan-Plessl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thea Johanne","family":"Gjerdingen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle Lu","family":"S\u00e6tersmoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna Julie","family":"Hoel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merete Thune","family":"Wiiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Olweus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn E.","family":"Wahlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole Christian","family":"Lingj\u00e6rde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda F.","family":"Cashen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1224-3478","authenticated-orcid":false,"given":"Marcus","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A.","family":"Fehniger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Holte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2699-3357","authenticated-orcid":false,"given":"Arne","family":"Kolstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8718-9373","authenticated-orcid":false,"given":"Karl-Johan","family":"Malmberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2020.10.006_bib1","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.critrevonc.2012.12.009","article-title":"Diffuse large B-cell lymphoma","volume":"87","author":"Martelli","year":"2013","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.medj.2020.10.006_bib2","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/bjc.2015.94","article-title":"Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK\u2019s Haematological Malignancy Research Network","volume":"112","author":"Smith","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.medj.2020.10.006_bib3","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/bjc.2011.450","article-title":"Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network","volume":"105","author":"Smith","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.medj.2020.10.006_bib4","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.medj.2020.10.006_bib5","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2020.10.006_bib6","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2020.10.006_bib7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.medj.2020.10.006_bib8","doi-asserted-by":"crossref","first-page":"6686","DOI":"10.1158\/1078-0432.CCR-13-1482","article-title":"Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies","volume":"19","author":"Coutinho","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2020.10.006_bib9","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1182\/blood-2010-12-322362","article-title":"Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"117","author":"Guti\u00e9rrez-Garc\u00eda","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.medj.2020.10.006_bib10","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma","volume":"329","year":"1993","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2020.10.006_bib11","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.medj.2020.10.006_bib12","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","article-title":"An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.medj.2020.10.006_bib13","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/bjh.14489","article-title":"Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of \u03b22-microglobulin yields a more accurate GELTAMO-IPI","volume":"176","author":"Montalb\u00e1n","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.medj.2020.10.006_bib14","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2020.10.006_bib15","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","article-title":"Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma","volume":"171","author":"Reddy","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.medj.2020.10.006_bib16","doi-asserted-by":"crossref","first-page":"e95192","DOI":"10.1371\/journal.pone.0095192","article-title":"Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability","volume":"9","author":"Assarsson","year":"2014","journal-title":"PLOS ONE"},{"issue":"D1","key":"10.1016\/j.medj.2020.10.006_bib17","doi-asserted-by":"crossref","first-page":"D506","DOI":"10.1093\/nar\/gky1049","article-title":"UniProt: a worldwide hub of protein knowledge","volume":"47","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.medj.2020.10.006_bib18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0377-0427(87)90125-7","article-title":"Silhouettes: a graphical aid to the interpretation and validation of cluster analysis","volume":"20","author":"Rousseeuw","year":"1987","journal-title":"J.\u00a0Comput. Appl. Math."},{"key":"10.1016\/j.medj.2020.10.006_bib19","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/1467-9868.00293","article-title":"Estimating the number of clusters in a data set via the gap statistic","volume":"63","author":"Tibshirani","year":"2001","journal-title":"J.\u00a0R. Stat. Soc. Series B Stat. Methodol."},{"key":"10.1016\/j.medj.2020.10.006_bib20","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","article-title":"MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.medj.2020.10.006_bib21","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1182\/blood-2013-07-517037","article-title":"Suboptimal dosing of rituximab in male and female patients with DLBCL","volume":"123","author":"Pfreundschuh","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.medj.2020.10.006_bib22","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2010-05-283820","article-title":"Immunosuppressive CD14+HLA-DR(low)\/- monocytes in B-cell non-Hodgkin lymphoma","volume":"117","author":"Lin","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.medj.2020.10.006_bib23","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1159\/000445644","article-title":"Prognostic Significance of Monocytes and Monocytic Myeloid-Derived Suppressor Cells in Diffuse Large B-Cell Lymphoma Treated with R-CHOP","volume":"39","author":"Wu","year":"2016","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.medj.2020.10.006_bib24","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","article-title":"Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity","volume":"125","author":"Sehn","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.medj.2020.10.006_bib25","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/(SICI)1521-4141(199801)28:01<290::AID-IMMU290>3.0.CO;2-S","article-title":"A soluble form of CD137 (ILA\/4-1BB), a member of the TNF receptor family, is released by activated lymphocytes and is detectable in sera of patients with rheumatoid arthritis","volume":"28","author":"Michel","year":"1998","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.medj.2020.10.006_bib26","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1053\/j.seminoncol.2010.09.013","article-title":"Signaling through OX40 enhances antitumor immunity","volume":"37","author":"Jensen","year":"2010","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.medj.2020.10.006_bib27","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/sj.leu.2403675","article-title":"Levels of soluble CD137 are enhanced in sera of leukemia and lymphoma patients and are strongly associated with chronic lymphocytic leukemia","volume":"19","author":"Furtner","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.medj.2020.10.006_bib28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0022-1759(01)00424-0","article-title":"Identification of a soluble OX40 isoform: development of a specific and quantitative immunoassay","volume":"255","author":"Taylor","year":"2001","journal-title":"J.\u00a0Immunol. Methods"},{"key":"10.1016\/j.medj.2020.10.006_bib29","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","article-title":"CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation - a target for novel cancer therapy","volume":"63","author":"Tokunaga","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.medj.2020.10.006_bib30","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1002\/cam4.934","article-title":"CXCL9: evidence and contradictions for its role in tumor progression","volume":"5","author":"Ding","year":"2016","journal-title":"Cancer Med."},{"key":"10.1016\/j.medj.2020.10.006_bib31","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1182\/blood-2014-06-583369","article-title":"Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma","volume":"125","author":"Mir","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.medj.2020.10.006_bib32","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.V82.7.2169.2169","article-title":"Serum interleukin-10 in non-Hodgkin\u2019s lymphoma: a prognostic factor","volume":"82","author":"Blay","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.medj.2020.10.006_bib33","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1182\/blood-2011-10-388538","article-title":"Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation","volume":"119","author":"Gupta","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.medj.2020.10.006_bib34","doi-asserted-by":"crossref","first-page":"101335","DOI":"10.1016\/j.smim.2019.101335","article-title":"Title: IL-10-producing T\u00a0cells and their dual functions","volume":"44","author":"Bedke","year":"2019","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.medj.2020.10.006_bib35","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1073\/pnas.89.5.1890","article-title":"Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes","volume":"89","author":"Rousset","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.medj.2020.10.006_bib36","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3109\/10428194.2011.621566","article-title":"Interleukin-6 plasma levels are modulated by a polymorphism in the NF-\u03baB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma","volume":"53","author":"Giachelia","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.medj.2020.10.006_bib37","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3109\/10428194.2012.660627","article-title":"Serum soluble CD27 level is associated with outcome in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone","volume":"53","author":"Goto","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.medj.2020.10.006_bib38","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/leu.2016.385","article-title":"Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients","volume":"31","author":"Rossille","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.medj.2020.10.006_bib39","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1038\/leu.2014.137","article-title":"High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-cell lymphoma: results from a French multicenter clinical trial","volume":"28","author":"Rossille","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.medj.2020.10.006_bib40","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/s41590-019-0441-y","article-title":"PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance","volume":"20","author":"Verma","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.medj.2020.10.006_bib41","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for Relapsed\/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having\u00a0Failed Autologous Transplantation: A Single-Arm, Phase II Study","volume":"37","author":"Ansell","year":"2019","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.medj.2020.10.006_bib42","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.medj.2020.10.006_bib43","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.biopha.2015.08.037","article-title":"Prognostic value of PD-1 and TIM-3 on CD3+ T\u00a0cells from diffuse large B-cell lymphoma","volume":"75","author":"Zhang","year":"2015","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.medj.2020.10.006_bib44","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1002\/cam4.874","article-title":"PD-1 expression on the surface of peripheral blood CD4+ T\u00a0cell and its association with the prognosis of patients with diffuse large B-cell lymphoma","volume":"5","author":"Zhang","year":"2016","journal-title":"Cancer Med."},{"key":"10.1016\/j.medj.2020.10.006_bib45","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","article-title":"PD-1 expression and clinical PD-1 blockade in B-cell lymphomas","volume":"131","author":"Xu-Monette","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.medj.2020.10.006_bib46","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/2326-6066.CIR-18-0439","article-title":"Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL","volume":"7","author":"Xu-Monette","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.medj.2020.10.006_bib47","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1186\/s12885-018-5086-y","article-title":"Prognostic role of myeloid-derived suppressor cells in cancers: a systematic review and meta-analysis","volume":"18","author":"Ai","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.medj.2020.10.006_bib48","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood-2015-08-662783","article-title":"T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells","volume":"128","author":"Azzaoui","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.medj.2020.10.006_bib49","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1741-7015-10-87","article-title":"The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem?","volume":"10","author":"Diamandis","year":"2012","journal-title":"BMC Med."},{"key":"10.1016\/j.medj.2020.10.006_bib50","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrc1322","article-title":"Rules of evidence\u00a0for cancer molecular-marker discovery and validation","volume":"4","author":"Ransohoff","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.medj.2020.10.006_bib51","series-title":"Immuno-Oncology Validation Data: Olink Proteomics","year":"2019"},{"key":"10.1016\/j.medj.2020.10.006_bib52","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood.2019003535","article-title":"Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report","volume":"135","author":"Lacy","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.medj.2020.10.006_bib53","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.medj.2020.10.006_bib54","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1093\/nar\/gkr424","article-title":"Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood","volume":"39","author":"Lundberg","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.medj.2020.10.006_bib55","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1001\/jama.1982.03320430047030","article-title":"Evaluating the\u00a0yield of medical tests","volume":"247","author":"Harrell","year":"1982","journal-title":"JAMA"}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634020300234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634020300234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T02:53:41Z","timestamp":1763002421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634020300234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S2666634020300234"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2020.10.006","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Systemic Protein Deviation Score Linked to PD-1+ CD8+ T Cell Expansion That Predicts Overall Survival in Diffuse Large B Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2020.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}